Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047762 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00047762: Completed Phase 1 study, sponsored by Genentech.
NCT00047762 is a Phase 1 study that has completed, run by Genentech. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047762, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
Interventions
- DRUG Erlotinib (aka Tarceva or OSI-774)
- DRUG Bevacizumab (aka Avastin or Rhu MAb VEGF)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Phase | Phase 1 |
What the finished NCT00047762 record still lists
NCT00047762 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib (aka Tarceva or OSI-774) is the first listed.
NCT00047762 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047762 about?
NCT00047762 is a clinical study titled "Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer". The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
What is the current status of trial NCT00047762?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-10.
What interventions are being tested in trial NCT00047762?
The interventions under investigation include: Erlotinib (aka Tarceva or OSI-774) (DRUG), Bevacizumab (aka Avastin or Rhu MAb VEGF) (DRUG).
Who is sponsoring clinical trial NCT00047762?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia